Iproplatin toxicity

Lind MJ, McGregor J, Timms MS, Brown D, Palmer P. Comparative toxicity of cisplatin, carboplatin (CBDCA) and iproplatin (CHIP) in combination with cyclophosphamide in patients with advanced epithelial ovarian cancer. Eur J Cancer Clin Oncol 1988 24(9) 1471-9. 

Toxicity. Iproplatin has less renal toxicity than cisplatin in rats at levels eliciting comparable gastrointestinal and bone marrow toxicity [139]. Similar results were seen in mice, where (17) caused severe leukopoenia but no azotaemia at high doses [97]. Studies in dogs indicated that iproplatin caused vomiting to about the same extent as cisplatin [48]. 

In conclusion, iproplatin appears to be less active and more toxic than carboplatin. Its future clinical role is limited. 

Both cisplatin and carboplatin are currently in clinical use. The ethylenediamine derivative (4.13) is active but somewhat toxic. Some Pt(TV) complexes such as iproplatin (4.15) are also active and are presumably reduced to Pt(Il) complexes in the body. 

---